NCT00566345 - Efficacy Study of an Investigational Influenza Vaccine (Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection (CCII) | Biotech Hunter

Enrollment

3,670

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions

Influenza

Interventions

BIOLOGICAL

Inactivated seasonal influenza vaccine (split virus, Vero cell-derived)

Trivalent, non-adjuvanted vaccine; dose: 0.5 ml

OTHER

Phosphate buffered saline

Packaged in syringes identical to those used for the investigational vaccine; dose: 0.5 ml

Trial Locations (34)

Unknown

Tucson

Anaheim

Sacramento

San Diego

San Francisco

Clearwater

Jacksonville

Pembroke Pines

South Miami

Chicago

Lenexa

Overland Park

Lexington

Metairie

Columbia

Kansas City

St Louis

Omaha

Las Vegas

Rochester

Charlotte

Raleigh

Winston-Salem

Goose Creek

Spartanburg

Nashville

Austin

Dallas

Fort Worth

Plano

San Angelo

San Antonio

Salt Lake City

Norfolk

All Listed Sponsors

lead

Alachua Government Services, Inc.

INDUSTRY